Randomized Phase III Trial of Avatrombopag, a Novel Oral Thrombopoietin Receptor Agonist, in Previously Treated Chronic ITP

December 9-12, 2017; Atlanta, Georgia
Cumulative duration of platelet response ≥ 50 x 109/L without rescue therapy was superior with avatrombopag vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 254 KB
Released: December 15, 2017


This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation

Related Content

Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD Released: June 28, 2022

Downloadable slideset from a local live webinar developed by gynecologic oncology experts with guidance on the management of relapsed cervical cancer

Linda R. Duska, MD, MPH Ritu Salani, MD, MBA Shannon N. Westin, MD, MPH Released: June 28, 2022

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: June 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings